ESBA105
Phase 2Biologic
ESBA105 is one of 21 biologic programs targeting Anterior Uveitis. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Anterior Uveitis
#DrugCompanyPhaseTrials
1Rinvoq
AbbVieApproved
Cimzia
UCBApproved
Tobrex
VViatris Specialty LLC
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Pred Forte
NovartisPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Olumiant
Eli LillyPhase 3
Acthar
MMallinckrodt
Approved
Myambutol
VVA Greater Los Angeles Healthcare System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ESBA105. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- EESBATech AG